These findings suggest that lenalidomide effectively inhibits DLBCL cell proliferation and invasion by modulating the CCL21/CCR7/ERK1/2 axis, highlighting its potential as a therapeutic target in DLBCL. This evidence concerns the gene CCR7 and diffuse large B-cell lymphoma.